Stopping adalimumab treatment for children with arthritis-related eye inflammation
Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Stopping Trial
This study is looking at what happens when kids with juvenile idiopathic arthritis stop taking adalimumab, a medicine for eye inflammation, to see if they can safely go off it without their symptoms coming back.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-10626013 on NIH RePORTER |
What this research studies
This research investigates the effects of stopping adalimumab, a medication used to treat eye inflammation associated with juvenile idiopathic arthritis (JIA), in children whose condition is currently under control. The study will involve multiple centers and will randomly assign participants to either continue or stop the medication, while monitoring for any recurrence of inflammation. By comparing the rates and timing of any flare-ups, the research aims to establish guidelines for safely discontinuing treatment. This could help reduce the financial burden and risks associated with long-term medication use.
Who could benefit from this research
Good fit: Ideal candidates for this research are children diagnosed with juvenile idiopathic arthritis who are currently experiencing controlled uveitis.
Not a fit: Patients who are not currently experiencing controlled uveitis or those who have not been treated with adalimumab may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide clearer guidelines for safely stopping adalimumab, potentially reducing treatment costs and minimizing the risk of side effects for patients.
How similar studies have performed: Previous research has shown that stopping and restarting anti-TNF-α therapy can affect responsiveness, indicating that this area of study is both relevant and necessary.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Acharya, Nisha — University of California, San Francisco
- Study coordinator: Acharya, Nisha
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.